As these genes are markers of BRD4 inhibition in this disease [7], we infer that these genes reflect differences in drug uptake in the tumors, a likely cause of variability in tumor growth dynamics in the group of animals treated with BMS-986158. This evidence concerns the gene BRD4 and neoplasm.